PolyPid
PYPD · NASDAQ
$5.15+$0.27 (+5.53%)TodayMarket closed ·
Prev close $4.88
About PYPD
- Employees
- 69
- Headquarters
- Petah Tikva, Central(HaMerkaz)
- Listed
- Jun 26, 2020
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Website
- polypid.com
PYPD key statistics
- Market cap
- 104.61M
- Price-earnings ratio
- 0.00
- Dividend yield
- —
- Average volume
- 94.02K
- Volume
- 109.52K
- Open price
- $4.88
- High today
- $5.17
- Low today
- $4.77
- 52 Week high
- $5.73
- 52 Week low
- $3.10
PolyPid (PYPD) at a glance
PolyPid (PYPD) last traded at $5.15, with a market cap of 104.61M and a price-to-earnings ratio of 0.00.
Today the stock has traded between $4.77 and $5.17. The current price is 8.0% above the day's low and 0.4% below its high.
Volume so far is 109.52K shares, in line with the average of 94.02K shares a day.
Over the past year PolyPid has ranged from $3.10 to $5.73, and now sits 78% of the way up that range.
PolyPid met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.35 per share against an estimate of -$0.3858.
The average analyst price target is $11.98, 132.7% above the current price, from 2 recent ratings.
Analyst ratings
Latest rating from each analyst over the past 12 months
100%of 2 analyst ratings say Buy
- Buy100.0%
- Hold0.0%
- Sell0.0%
Price target · 6 analystsAvg $11.98
- Low
- $8.08
- Now
- $5.15
- High
- $14.70
PYPD earnings
Earnings per share, reported against the analyst estimate
Beat the estimate in 4 of the last 8 quarters, by 18.6% on average.
- Q3 FY24: reported -$1.22 per share against an estimate of -$1.02
- Q4 FY24: reported -$1.09 per share against an estimate of -$0.894
- Q1 FY25: reported -$0.70 per share against an estimate of -$0.8126
- Q2 FY25: reported -$0.78 per share against an estimate of -$0.5585
- Q3 FY25: reported -$0.37 per share against an estimate of -$0.5329
- Q4 FY25: reported -$0.41 per share against an estimate of -$0.3361
- Q1 FY26: reported -$0.35 per share against an estimate of -$0.442
- Q2 FY26: reported -$0.35 per share against an estimate of -$0.3858
PYPD news
- Vandana Singh
Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial
- Press releaseGlobe Newswire
BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript
A Look Ahead: PolyPid's Earnings Forecast
PolyPid's Earnings: A Preview
- Avi Kapoor
Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
Similar companies
Companies in the same industry as PolyPid
Most active stocks
Highest trading volume today
- EARIEntertainment Arts Research$0.0003−16.67%
- SEIISharing Economy International$0.0004+100.00%
- NWGLCL Workshop Group$0.1522+27.90%
- TMSHTrans Global Assets$0.0002+0.00%
- AEFIAmerican EcoFuels$0.0007+0.00%
- CBDW1606$0.0002+0.00%
- FITYFifty 1 Labs$0.0001−66.67%
- PRSOPeraso$0.5914+54.13%
- SDSTStardust Power$0.02−23.66%
- SHFSSHF Holdings$0.0899−4.36%
- FRTTFort Technology$0.7121+32.63%
- CBDLCBD Life Sciences$0.0002−25.00%
Newly listed
Companies that went public in the past six weeks
- TCXBTCGX Acquisition Corp. II$10.56+1.54%
- CTYCITY THERAPEUTICS$20.83−2.94%
- IAMIambic Therapeutics$16.01−2.02%
- AMROAmaero$5.68+1.25%
- FLSCFrazier Life Sciences Acquisition Corp. II$10.28−0.10%
- TRXBTRex Bio$14.44−2.43%
- RTSNRetension Pharmaceuticals$16.18−0.92%
- PAXGUPine Tree Acquisition$9.98+0.00%
- PORTUSouthport Acquisition Corp. IIListed Oct 1, 2026
- CHWMChilwa Minerals$5.18+3.39%
- ACCVAccelevation Holdings$12.31−1.44%
- RZAIROZE AI$10.28+1.28%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.